Vivos Therapeutics Statistics
Share Statistics
Vivos Therapeutics has 5.89M
shares outstanding. The number of shares has increased by 73.39%
in one year.
Shares Outstanding | 5.89M |
Shares Change (YoY) | 73.39% |
Shares Change (QoQ) | 21.8% |
Owned by Institutions (%) | 0.33% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 991 |
FTD / Avg. Volume | 1.03% |
Short Selling Information
The latest short interest is 259.4K, so 4.4% of the outstanding
shares have been sold short.
Short Interest | 259.4K |
Short % of Shares Out | 4.4% |
Short % of Float | 4.89% |
Short Ratio (days to cover) | 3.05 |
Valuation Ratios
The PE ratio is -1.93 and the forward
PE ratio is -2.45.
Vivos Therapeutics's PEG ratio is
0.02.
PE Ratio | -1.93 |
Forward PE | -2.45 |
PS Ratio | 1.43 |
Forward PS | 0.7 |
PB Ratio | 2.71 |
P/FCF Ratio | -1.62 |
PEG Ratio | 0.02 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Vivos Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.5,
with a Debt / Equity ratio of 0.19.
Current Ratio | 1.5 |
Quick Ratio | 1.5 |
Debt / Equity | 0.19 |
Debt / EBITDA | -0.14 |
Debt / FCF | -0.11 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $137,899.08 |
Profits Per Employee | $-102,165.14 |
Employee Count | 109 |
Asset Turnover | 0.98 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 16.84% in the
last 52 weeks. The beta is 7.27, so Vivos Therapeutics's
price volatility has been higher than the market average.
Beta | 7.27 |
52-Week Price Change | 16.84% |
50-Day Moving Average | 2.69 |
200-Day Moving Average | 3.25 |
Relative Strength Index (RSI) | 41.01 |
Average Volume (20 Days) | 96,430 |
Income Statement
In the last 12 months, Vivos Therapeutics had revenue of 15.03M
and earned -11.14M
in profits. Earnings per share was -1.68.
Revenue | 15.03M |
Gross Profit | 9.02M |
Operating Income | -11.17M |
Net Income | -11.14M |
EBITDA | -10.55M |
EBIT | -11.17M |
Earnings Per Share (EPS) | -1.68 |
Full Income Statement Balance Sheet
The company has 6.26M in cash and 1.51M in
debt, giving a net cash position of 4.75M.
Cash & Cash Equivalents | 6.26M |
Total Debt | 1.51M |
Net Cash | 4.75M |
Retained Earnings | -104.19M |
Total Assets | 11.28M |
Working Capital | -1.09M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -12.69M
and capital expenditures -568K, giving a free cash flow of -13.26M.
Operating Cash Flow | -12.69M |
Capital Expenditures | -568K |
Free Cash Flow | -13.26M |
FCF Per Share | -2.64 |
Full Cash Flow Statement Margins
Gross margin is 60%, with operating and profit margins of -74.32% and -74.09%.
Gross Margin | 60% |
Operating Margin | -74.32% |
Pretax Margin | -74.09% |
Profit Margin | -74.09% |
EBITDA Margin | -70.22% |
EBIT Margin | -74.32% |
FCF Margin | -88.21% |